Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL999040 | 0.89 | DRD2 (0.43) | HTR2C | |
| SCHEMBL999284 | 0.89 | SLC18A3 (0.50) | SLC18A3SIGMAR1HTR2C | |
| SCHEMBL28706235 | 0.84 | CHRNB4 (0.45) | SLC18A3SIGMAR1 | |
| SCHEMBL694970 | 0.82 | SLC18A3 (0.44) | SLC18A3SIGMAR1HTR2C | |
| SCHEMBL24524 | 0.78 | — | — | |
| SCHEMBL42932 | 0.74 | — | — | |
| SCHEMBL43137 | 0.74 | PTPN1 (0.32) | SLC18A3 | |
| SCHEMBL5790547 | 0.74 | HPGD (0.44) | SLC18A3SIGMAR1HTR2C | |
| SCHEMBL25216 | 0.72 | CYP11B2 (0.34) | SLC18A3 | |
| SCHEMBL7838054 | 0.72 | CYP11B2 (0.34) | SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023217539-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2023-11-16 | — | — | WO | claimed |
| EP-4276093-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM | Consejo Superior De Investigaciones Científicas (ES) | 2023-11-15 | — | — | EP | claimed |
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | claimed |
| EP-2292613-B1 | DIHYDROINDOLINONE DERIVATIVES | SHANGHAI INST PHARM INDUSTRY (CN) | 2015-09-30 | — | — | EP | claimed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | claimed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | claimed |
| US-8399454-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-19 | — | — | US | claimed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | claimed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | claimed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | claimed |
| CN-1993331-A | N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer | CHIRON CORP (US) | 2007-07-04 | — | — | CN | claimed |
| EP-1765789-A1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060009472-A1 | Substituted imidazole derivatives | CHIRON CORPORATION | 2006-01-12 | — | — | US | claimed |
| WO-2006002236-A1 | N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | claimed |
| WO-2004017966-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS IN THE TREATMENT OF CHRONIC AND ACUTE PAIN | IONIX PHARMACEUTICALS LIMITED (GB) | 2004-03-04 | — | — | WO | claimed |
| WO-2001056974-A2 | INHA INHIBITORS AND THEIR USE AS ANTIBACTERIALS | GENZYME CORPORATION (US) | 2001-08-09 | — | — | WO | claimed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | claimed |
| US-6030969-A | ADENOSINE KINASE INHIBITORS; ANTIISCHEMIA,-INFLAMMATORY, -DIABETIC AGENTS; NEUROLOGICAL AND GASTROINTESTINAL DISORDERS; NOCIPERCEPTION, IMMUNOSUPPRESSION; SEPSIS | ABBOTT LABORATORIES (US) | 2000-02-29 | — | — | US | claimed |
| EP-0979230-A1 | 6,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | Abbott Laboratories (US) | 2000-02-16 | — | — | EP | claimed |
| WO-1998046603-A1 | 6,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009472-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | SLC18A3 259/4885SIGMAR1 583/4885HTR3A 756/4885 |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | ABCG2, CYP2C19, AADAC | SLC18A3 259/4885SIGMAR1 583/4885HTR3A 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.